Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6559158 | SALIX PHARMS | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov, 2017
(6 years ago) | |
US8552025 | SALIX PHARMS | Stable methylnaltrexone preparation |
Apr, 2024
(10 days ago) | |
US10376584 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(10 days ago) | |
US9669096 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(10 days ago) | |
US8420663 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US8822490 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9492445 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9180125 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US8247425 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Dec, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6559158 | SALIX | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov, 2017
(6 years ago) | |
US8420663 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9724343 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9180125 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9492445 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US8524276 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(6 years from now) | |
US10307417 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(6 years from now) | |
US8956651 | SALIX | Oral formulations and lipophilic salts of methylnal trexone |
Mar, 2031
(6 years from now) | |
US9314461 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(6 years from now) | |
US10376505 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 19, 2019 |
Market Authorisation Date: 19 July, 2016
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL